CA209143: A Randomized Phase IIB Open Label Study of Nivolumab or Nivolumab in Combination with Ipilimumab versus Bevacizumab in Adult Subjects with Recurrent Glioblastoma (GBM)
Cancer - Brain
- Subjects with histologically confirmed Grade IV malignant glioma
- Previous treatment with radiotherapy and temozolomide
- Documented first recurrence of GBM
- Karnofsky performance status (PS) = 70
Please contact us for a full list of eligibility requirements.